A new drug slated to undergo clinical study for major depressive disorder (MDD) shows promise for delivering the needed therapeutic effect to patients without triggering some of the more common side effects associated with anti-depressants.
Specifically, the drug provides a unique method of action that works as a dual enhancer of serotonin and dopamine in the brain.
Phase IIb Study of Serdaxin Underway for Treatment of Major Depressive Disorder
Комментариев нет:
Отправить комментарий